Enzalutamide

Drug Overview

Enzalutamide is a potent, oral androgen receptor (AR) inhibitor used in the treatment of prostate cancer. It is classified as a second-generation anti-androgen, designed to block the androgen signaling pathway that drives prostate cancer growth, making it a critical Targeted Therapy agent.

• Generic Name: Enzalutamide
• US Brand Names: Xtandi®
• Drug Class: Androgen Receptor Signaling Inhibitor, Hormone Therapy. This is a highly selective Targeted Therapy and a Smart Drug.
• Route of Administration: Oral Capsule or Tablet
• FDA Approval Status: Approved for the treatment of multiple stages of prostate cancer, including non-metastatic and metastatic castration-resistant prostate cancer (CRPC), and metastatic castration-sensitive prostate cancer (CSPC).

What Is It and How Does It Work? (Mechanism of Action)

Enzalutamide is a non-steroidal anti-androgen that acts by binding with high affinity to the androgen receptor (AR), preventing androgens (like testosterone) from signaling the prostate cancer cell to grow and survive.

• Inhibition of Nuclear Translocation: After activation, the AR complex typically moves from the cell cytoplasm into the nucleus (nuclear translocation) to regulate gene expression. Enzalutamide inhibits this movement.
• Impairment of DNA Binding and Transcription: By keeping the AR complex in the cytoplasm or preventing its binding to the DNA, Enzalutamide prevents the transcription of AR-target genes (e.g., PSA) that promote tumor cell growth and survival.
• Result (Cell Cycle Arrest and Apoptosis): The triple blockade effectively silences the androgen signaling axis, leading to cell cycle arrest and apoptosis (programmed cell death) of the prostate cancer cells.
• Bone Affinity: Not applicable. Enzalutamide is a systemic oral hormone therapy agent and does not possess selective affinity for bone mineral components.

FDA Approved Clinical Indications

Enzalutamide is approved for use across the spectrum of advanced prostate cancer, significantly delaying progression and improving survival in both hormone-sensitive and castration-resistant settings.

Oncological Uses

1. Non-metastatic Castration-Resistant Prostate Cancer (nmCRPC): Used in patients with rising Prostate-Specific Antigen (PSA) levels despite androgen deprivation therapy (ADT).
2. Metastatic Castration-Resistant Prostate Cancer (mCRPC): Used in patients whose cancer has progressed despite prior ADT.
3. Metastatic Castration-Sensitive Prostate Cancer (mCSPC): Used in combination with ADT as a first-line therapy for men whose cancer has metastasized but is still responsive to androgen suppression.

Non-oncological Uses

1. There are currently no FDA-approved non-oncological indications for Enzalutamide.
2. Its mechanism is specific to the androgen signaling pathway driving cancer.

Dosage and Administration Protocols

Enzalutamide is taken orally once daily, regardless of whether it is used as monotherapy (in nmCRPC) or in combination with standard ADT.

• Dose Reduction: Dose reduction (e.g., to 120 mg daily, then 80 mg daily) is necessary for managing adverse reactions, particularly severe neurological events (seizures) or Grade 3/4 toxicities.
• Renal Insufficiency: No dose adjustment is required for mild to severe renal impairment.
• Hepatic Insufficiency: Dose reduction (e.g., to 80 or 120 mg daily) is required for patients with severe hepatic impairment (Child-Pugh Class C) due to altered drug metabolism.

Standard Dosing for Oncological Indications (All Approved Settings)

Clinical Efficacy and Research Results

Enzalutamide has demonstrated impressive clinical efficacy across pivotal trials, extending Progression-Free Survival (PFS) and Overall Survival (OS) in men with advanced prostate cancer.

• Non-metastatic CRPC (PROSPER Trial – 2020-2025 Context): Enzalutamide significantly increased the median Metastasis-Free Survival (MFS) by over two years (36.6 months vs. 14.7 months for placebo), confirming its profound effect in delaying disease spread.
• Metastatic CSPC (ARCHES Trial – 2020-2025 Context): When added to standard ADT, Enzalutamide improved the 3-year survival rate, reducing the risk of radiographic progression or death by 61 percent (Hazard Ratio of 0.39).
• Metastatic CRPC (AFFIRM Trial): Demonstrated a median OS benefit of 4.8 months over placebo in post-chemotherapy patients, leading to its initial FDA approval.
• Durable Remissions: The median PFS in the metastatic settings can range from 18 to over 30 months, depending on prior treatment, highlighting its potency and durability.

Safety Profile and Side Effects

Black Box Warning

The primary safety concerns with Enzalutamide relate to central nervous system (CNS) effects, particularly seizures, and risks associated with accelerated bone loss.

Common Side Effects (Greater than 10 percent)

• Systemic: Asthenia (fatigue, highly common), hot flashes (due to castration), headache.
• Musculoskeletal: Arthralgia (joint pain), back pain.
• Cardiovascular: Hypertension (high blood pressure).

Serious Adverse Events

1. Seizures: Enzalutamide can lower the seizure threshold. This risk is dose-dependent and necessitates caution in patients with a history of seizures.
2. Posterior Reversible Encephalopathy Syndrome (PRES): A rare but serious neurological condition causing headaches, seizures, and visual disturbances.
3. Fractures: Increased risk of bone fractures due to accelerated bone mineral density loss from long-term androgen deprivation.

Connection to Stem Cell and Regenerative Medicine

Enzalutamide supports regenerative medicine principles by preserving the patient’s quality of life and facilitating long-term health management through bone support.

• Bone Health Regeneration: Long-term ADT and AR inhibition cause bone loss. The standard management involves using bone-targeting therapies (bisphosphonates or denosumab) that stimulate bone matrix repair and regeneration, significantly reducing the risk of fractures and maintaining patient mobility and skeletal integrity.
• Quality of Life Preservation: By providing effective, non-chemotherapy disease control, Enzalutamide helps maintain functional status and fitness, which is crucial for overall quality of life and eligibility for potential future curative therapies, including advanced cellular therapies or surgery.

Patient Management and Practical Recommendations

Pre-treatment Tests to Be Performed

Given the potential for neurological and cardiovascular side effects, patient counseling and close monitoring are essential.

• Hormone Status: Baseline Prostate-Specific Antigen (PSA) and testosterone levels.
• Cardiovascular: Baseline blood pressure assessment and initiation of treatment for hypertension if necessary.

Precautions During Treatment

• Seizure Watch: Caution patients to avoid activities where a sudden loss of consciousness (due to a seizure) could be dangerous (e.g., driving, operating heavy machinery).
• Blood Pressure Control: Blood pressure must be monitored weekly for the first month and regularly thereafter.

Do’s and Don’ts List

• DO adhere strictly to your blood pressure medication regimen.
• DO report any signs of confusion, severe headache, dizziness, or muscle twitching immediately.
• DON’T consume grapefruit juice, as it can potentially alter the drug’s metabolism.
• DON’T drive or operate heavy machinery until you are certain the medication is not causing dizziness or lightheadedness.

Legal Disclaimer

The information provided herein regarding Enzalutamide (Xtandi®) is intended for general informational purposes only and is directed towards an international audience of patients and healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or personalized treatment from a qualified oncologist. This drug involves risks including seizures, fractures, and severe hypertension. All individuals must consult their specific healthcare provider for information tailored to their medical condition and treatment regimen. Reliance on any information appearing on this guide is solely at your own risk.